EDAP Heightens Participation in Global Urology Congresses
August 31 2010 - 9:03AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today that it will actively pursue its
communication, education and marketing strategy by participating in
select highly-regarded worldwide urology events.
Earlier this month, EDAP highlighted its technologies at
the Asian Congress of Urology. In September, EDAP's sales and
marketing team will participate in the 28th World Congress of
Endourology and Shock Wave Lithotripsy (WCE & SWL), to be held
in Chicago-Hotel Sheraton on September 1-3, 2010. Five abstracts
will be presented specifically on the use of Ablatherm-HIFU as
primary care and salvage for prostate cancer and the positive
results achieved.
HIFU is clearly becoming a regarded minimally invasive option
for urology pathologies. This position is reflected by other
speakers at the WCE & SWL who are planning to refer to HIFU
technology in addressing focal therapy of prostate cancer, in
discussing HIFU's approach to tumors beyond prostate or in
comparing HIFU to existing robotic approaches. Pr. Christian
Chaussy, Munich, Germany, a long-term experienced Ablatherm-HIFU
user, will be moderating a debate on focal therapy for prostate
cancer, addressing clinical trial options to validate this
promising enhanced therapeutic approach.
Throughout September 2010, EDAP will pursue its communications
and marketing efforts during the European Urology Week, to be held
on September 13-17 2010. EDAP will be sponsoring public relations
programs in Europe aimed at raising public awareness about prostate
cancer and Ablatherm-HIFU positive outcomes.
On September 22-25, 2010, EDAP TMS Germany based subsidiary will
be attending the 62nd Annual Congress of the German Society of
Urology (DGU) to be held in Dusseldorf, Germany (booth # 4.14),
where EDAP's new compact lithotripter Sonolith i-move will be
showcased. EDAP will also take this opportunity to present and
launch a new multi-centric HIFU Study among Ablatherm-HIFU German
users, allowing registration of their clinical results into EDAP's
global Registry database.
Marc Oczachowski, Chief Executive Officer of EDAP TMS,
commented, "Our sales and marketing teams remain very much
committed to implementing focused marketing initiatives and in
promoting our technologies. We will continue to actively
work with the Urology community to position HIFU as the preferred
solution to address prostate cancer and particularly its ability to
focally approach localized prostate cancer tumors."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multicenter U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA.
The Company also is developing this technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment for treatment of
urinary tract stones using extra-corporeal shockwave lithotripsy
(ESWL). For more information on the company, please visit
http://www.edap-tms.com, http://www.hifu-planet.com.
CONTACT: EDAP TMS SA
Investor Relations/Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
Stephanie Carrington
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024